Invivyd Inc is a pioneering biopharmaceutical company based in Waltham, Massachusetts, dedicated to combating infectious diseases. With a sharp focus on antibody-based solutions, its flagship product, adintrevimab, is making strides in Phase 3 clinical trials for COVID-19 treatment and prevention. Beyond adintrevimab, Invivyd is advancing other monoclonal antibodies like VYD222 and VYD224 against SARS-CoV-2, and exploring potential defenses against seasonal influenza. The company, evolving from Adagio Therapeutics in 2022, collaborates with notable institutions like Adimab, LLC, and the Scripps Research Institute to push the boundaries of infectious disease prevention and treatment.
Pre-Market Stock Futures: Futures are trading higher as we get ready to start a holiday-shortened trading week after an outstanding triple-witching Friday rally that may have kicked the “Santa Claus” rally into…
